275 related articles for article (PubMed ID: 28890796)
21. Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
[TBL] [Abstract][Full Text] [Related]
22. Multiple sclerosis hospitalizations among users of oral disease-modifying therapies.
Pham Nguyen TP; Jacobs D; Thibault D; Willis AW
Mult Scler Relat Disord; 2021 Jul; 52():102944. PubMed ID: 33894480
[TBL] [Abstract][Full Text] [Related]
23. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
24. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
[TBL] [Abstract][Full Text] [Related]
25. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
[TBL] [Abstract][Full Text] [Related]
26. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.
Vollmer B; Nair KV; Sillau SH; Corboy J; Vollmer T; Alvarez E
Mult Scler J Exp Transl Clin; 2017; 3(3):2055217317725102. PubMed ID: 28839949
[TBL] [Abstract][Full Text] [Related]
27. Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
Tanaka E; Watanabe M; Fukumoto S; Masaki K; Yamasaki R; Matsushita T; Isobe N
Mult Scler Relat Disord; 2023 Feb; 70():104513. PubMed ID: 36689892
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
Brownlee WJ; Haghikia A; Hayward B; Waser N; Kayaniyil S; Khan Z; Duncan J; Millar S; Harty GT
Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465
[TBL] [Abstract][Full Text] [Related]
29. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Boz C; Terzi M; Özer B; Turkoglu R; Karabudak R; Efendi H; Soysal A; Sevim S; Altintas A; Kurne A; Akçalı A; Akman G; Yüceyar N; Balcı BP; Ekmekci Ö; Karahan SZ; Demirkıran M; Altunrende B; Turan ÖF; Gökçen GözübatıkÇelik ; Kale N; Köseoğlu M; Ozakbas S
Mult Scler Relat Disord; 2019 Nov; 36():101376. PubMed ID: 31473488
[TBL] [Abstract][Full Text] [Related]
31. Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.
Spelman T; Horakova D; Ozakbas S; Alroughani R; Onofrj M; Kalincik T; Prat A; Terzi M; Grammond P; Patti F; Csepany T; Boz C; Lechner-Scott J; Granella F; Grand'Maison F; van der Walt A; Zhu C; Butzkueven H;
Mult Scler Relat Disord; 2023 Feb; 70():104477. PubMed ID: 36746088
[TBL] [Abstract][Full Text] [Related]
32. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis.
Paolicelli D; Manni A; Iaffaldano A; Trojano M
CNS Drugs; 2020 Jan; 34(1):65-92. PubMed ID: 31898276
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.
Longbrake EE; Cross AH; Salter A
Mult Scler J Exp Transl Clin; 2016; 2():. PubMed ID: 28280599
[TBL] [Abstract][Full Text] [Related]
36. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
[TBL] [Abstract][Full Text] [Related]
37. Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes
Hunter SF; Thomas FP; Cascione M; Williams IM; Meng X; Schofield L; Weiss JL; Tenenbaum N; Cree BAC;
Mult Scler Relat Disord; 2020 Oct; 45():102346. PubMed ID: 32717684
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.
Granqvist M; Burman J; Gunnarsson M; Lycke J; Nilsson P; Olsson T; Sundström P; Svenningsson A; Vrethem M; Frisell T; Piehl F
Mult Scler; 2020 Oct; 26(12):1532-1539. PubMed ID: 31392923
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
40. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.
Kremenchutzky M; O'Connor P; Hohlfeld R; Zhang-Auberson L; von Rosenstiel P; Meng X; Grinspan A; Hashmonay R; Kappos L
Mult Scler Relat Disord; 2014 May; 3(3):341-9. PubMed ID: 25876471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
